Warming up to a triple therapy for cervical cancer

McCaffrey, Pat

doi:10.1016/s1470-2045(05)70301-6

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In their study the mean peri-tumor temperature was 36.7 ± 0.2 °C before heating and increased to 38.5 ± 0.8 °C at the end of heating for 60 min. This increase of roughly 2 °C is in line with the studies on other heating techniques applied to cervical tumors (50) and provides evidence of the radiosensitising effects for mEHT based on improved blood flow and subsequent improved oxygen in the tumoral environment.…”

Section: Resultssupporting

confidence: 85%

Review of the Clinical Evidences of Modulated Electro-Hyperthermia (mEHT) Method: An Update for the Practicing Oncologist

et al. 2019

View full text Add to dashboard Cite

Background: Modulated electro-hyperthermia (mEHT) is a variation of the conventional hyperthermia which selectively targets the malignant cell membranes in order to heat the malignant tissue and sensitize the tissue to oncology treatments. Although widely applied, the formulation of guidelines for the use thereof is still in progress for many tumors.Aim: In this paper we review the literature on the effects of mEHT in cancer patients on local disease control and survival.Methodology: Our review on data presents the collected experience with capacitive hyperthermia treatments with the EHY-2000+ device (OncoTherm Ltd., Germany). A literature search was conducted in Pubmed and articles were grouped and discussed according to: trial type, animal studies, in vitro studies, and reviews. Search results from Conference Abstracts; Trial Registries; Thesis and Dissertations and the Oncothermia Journal were included in the discussions.Results: Modulated electro-hyperthermia is a safe form of hyperthermia which has shown to effectively sensitizes deep tumors, regardless of the thickness of the adipose layers. The technology has demonstrated equal benefits compared to other forms of hyperthermia for a variety of tumors. Given the effective heating ability to moderate temperatures, the improved tumor perfusion, and ability to increase drug absorption, mEHT is a safe and effective heating technology which can be easily applied to sensitize tumors which have demonstrated benefits with the addition of hyperthermia. Modulated electro-hyperthermia also appears to improve local control and survival rates and appears to induce an abscopal (systemic) response to ionizing radiation.Conclusion: Based on clinical studies, the method mEHT is a feasible hyperthermia technology for oncological applications. Concomitant utilization of mEHT is supported by the preclinical and clinical data.

show abstract

Section: Resultssupporting

confidence: 85%

Review of the Clinical Evidences of Modulated Electro-Hyperthermia (mEHT) Method: An Update for the Practicing Oncologist

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The advanced capability to deploy heat with more sophisticated modalities has led to a resurgence in interest in hyperthermia for cervical cancer especially in combination with either radiation or cisplatin (13,39). Recently, the combination of radiotherapy with hyperthermochemotherapy in a triple-modality treatment for advanced cervical cancer has been shown to increase both response rate and survival time in a phase II study and is currently in phase III trial (40,41). The results described herein show that a further improvement in sensitivity to hyperthermochemotherapy may be obtained by targeting HSF1.…”

Section: Discussionmentioning

confidence: 99%

Targeting the Heat Shock Factor 1 by RNA Interference: A Potent Tool to Enhance Hyperthermochemotherapy Efficacy in Cervical Cancer

Rossi

Ciafrè²,

Balsamo³

et al. 2006

Cancer Research

View full text Add to dashboard Cite

Carcinoma of the uterine cervix is one of the highest causes of mortality in female cancer patients worldwide, and improved treatment options for this type of malignancy are highly needed. Local hyperthermia has been successfully used in combination with systemic administration of cisplatin-based chemotherapy in phase I/II clinical studies. Heat-induced expression of cytoprotective and antiapoptotic heat shock proteins (HSP) is a known complication of hyperthermia, resulting in thermotolerance and chemoresistance and hindering the efficacy of the combination therapy. Heat shock transcription factor 1 (HSF1) is the master regulator of heatinduced HSP expression. In the present report, we used small interfering RNA (siRNA) to silence HSF1 and to examine the effect of HSF1 loss of function on the response to hyperthermia and cisplatin-based chemotherapy in HeLa cervical carcinoma. We have identified the 322-nucleotide to 340-nucleotide HSF1 sequence as an ideal target for siRNAmediated HSF1 silencing, have created a pSUPER-HSF1 vector able to potently suppress the HSF1 gene, and have generated for the first time human cancer cell lines with stable loss of HSF1 function. We report that, although it surprisingly does not affect cancer cell sensitivity to cisplatin or elevated temperatures up to 43°C when administered separately, loss of HSF1 function causes a dramatic increase in sensitivity to hyperthermochemotherapy, leading to massive (>95%) apoptosis of cancer cells. These findings indicate that disruption of HSF1-induced cytoprotection during hyperthermochemotherapy may represent a powerful strategy to selectively amplify the damage in cancer cells and identify HSF1 as a promising therapeutic target in cervical carcinoma. (Cancer Res 2006; 66(15): 7678-85)

show abstract

“…A review by Hildebrandt et al [2] reported that several clinical trials have demonstrated improved survival rates for pelvic tumor patients treated with combined radiotherapy and hyperthermia. A phase II study reported an improved outcome of a triple modality treatment, involving cisplatin, radiotherapy and hyperthermia, in patients having advanced cervical cancer and a phase III trial of the same for cervical cancer is on [3]. These literature evidences suggest the role of hyperthermia in cervical cancer treatment.…”

Section: Introductionmentioning

confidence: 95%

Effect of temperature on surface properties of cervical tissue homogenate and organic phase monolayers

Preetha

Banerjee

Huilgol

2007

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

Warming up to a triple therapy for cervical cancer

Cited by 3 publications

References 0 publications

Review of the Clinical Evidences of Modulated Electro-Hyperthermia (mEHT) Method: An Update for the Practicing Oncologist

Review of the Clinical Evidences of Modulated Electro-Hyperthermia (mEHT) Method: An Update for the Practicing Oncologist

Targeting the Heat Shock Factor 1 by RNA Interference: A Potent Tool to Enhance Hyperthermochemotherapy Efficacy in Cervical Cancer

Effect of temperature on surface properties of cervical tissue homogenate and organic phase monolayers

Contact Info

Product

Resources

About